BiotechTube

MK-0646

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neuroendocrine Tumors

Conditions

Neuroendocrine Tumors, Metastatic Neuroendocrine Tumors

Trial Timeline

Jan 1, 2008 → Jan 1, 2010

NCT ID
NCT00610129

About MK-0646

MK-0646 is a phase 2 stage product being developed by Merck for Neuroendocrine Tumors. The current trial status is completed. This product is registered under clinical trial identifier NCT00610129. Target conditions include Neuroendocrine Tumors, Metastatic Neuroendocrine Tumors.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00610129Phase 2Completed

Competing Products

20 competing products in Neuroendocrine Tumors

See all competitors
ProductCompanyStageHype Score
[203Pb]VMT-α-NET + [212Pb]VMT-α-NETPerspective TherapeuticsPhase 1/2
33
[203Pb]VMT-α-NETPerspective TherapeuticsPhase 1
25
[212Pb] VMT-α-NETPerspective TherapeuticsPhase 1
25
LenvatinibEisaiPhase 2
52
AbemaciclibEli LillyPhase 2
52
Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.Jiangsu Hengrui MedicinePhase 3
77
FamitinibJiangsu Hengrui MedicinePhase 2
52
68Ga-DOTATOCJiangsu Hengrui MedicinePhase 3
77
OlaparibAstraZenecaPhase 2
52
AvelumabMerckPhase 1/2
41
PembrolizumabMerckPhase 2
52
Lenvatinib + Pembrolizumab + Hyperpolarized 13C-PyruvateMerckPhase 2
52
PembrolizumabMerckPhase 2
52
Pembrolizumab InjectionMerckPhase 2
52
Carboplatin + Cisplatin + Docetaxel + Etoposide + PembrolizumabMerckPhase 1
33
AvelumabMerckPhase 2
52
Pembrolizumab + LenvatinibMerckPhase 2
52
AvelumabMerckPhase 2
52
Pembrolizumab + Irinotecan + PaclitaxelMerckPhase 2
52
Lanreotide + PembrolizumabMerckPhase 1/2
41

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85